Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoro-pentanamide
- Correlated keywords
- biochemical inhibitor Alzheimer’s research neuroscience BMS708163 inhibit ?-secretase protease enzyme complex cleave single-pass transmembrane protein Notch receptor ?-amyloid precursor protein ?APP ?-APP domain orally bioavailable cleavage A?40 pharmacokinetic rat dog human blood-brain barrier BBB plasma brain cerebrospinal fluid CSF reduce level A?38 A?42 increase ?-C-terminal fragment ?CTF in vitro vivo cell function Notch-sparing BMS 708163-01
- Product Overview:
?-Secretase is a protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors and ?-amyloid precursor protein (APP), within the transmembrane domain.{27051,25415} Avagacestat is a potent, orally bioavailable inhibitor of ?-secretase that more potently inhibits the cleavage of APP to A?40 than signaling through Notch (IC50s = 0.30 and 58 nM, respectively).{27425} It shows good pharmacokinetics in rats, dogs, and humans and passes the blood-brain barrier, reducing plasma, brain, and cerebrospinal fluid A?40 levels.{27425,27428} While suppressing the production of A?38, A?40, and A?42, ?-secretase inhibitors, including avagacestat, increase the level of APP ?-C-terminal fragment, both in vitro and in vivo, altering cell function.{27426} Avagacestat may impact Notch signaling in vivo, although it is generally considered a “Notch-sparing” ?-secretase inhibitor.{27427}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.